检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
机构地区:[1]武汉大学人民医院心血管内科,湖北武汉430060
出 处:《海南医学院学报》2012年第11期1526-1528,1536,共4页Journal of Hainan Medical University
基 金:国家自然基金青年基金(81100130)~~
摘 要:目的:探讨血浆miR-143和miR-145水平与冠脉粥样硬化严重程度的关系。方法:112例患者按冠脉造影结果分为冠脉病变组、非显著冠脉病变组和对照组,用Gensini评分评估病变严重程度。用实时定量RT-PCR检测血浆中miR-143和miR-145的浓度,并评估其与冠脉粥样硬化严重程度的关系。结果:与非显著冠脉病变组和对照组相比,冠脉病变组患者血浆miR-143和miR-145水平显著降低。miR-143和miR-145是冠脉粥样硬化严重程度的独立危险因素(miR-143,r=-0.440,P=0.001;miR-145,r=-0.459,P=0.015)。miR-143和miR-145的ROC曲线下面积分别为0.884和0.909。结论:miR-143和miR-145可作为评估冠脉粥样硬化程度的生物标志物,并具有较高的特异性和敏感性。Objective,- To investigate relationship between miK-i4~, mux-~~o anu t,le be y u, coronary atherosclerosis. Methods: The plasma levels of miR-143 and miR-145 were examined by real-time RT-PCR in 112 subjects, which were divided into coronary artery disease group (CAD)group, non-signifi- cant CAD group and healthy group according to angiography results, miR-143 and miR-145 were measured by RT-PCR, and the relationship between them severity o[ coronary atherosclerosis was also analyzed. Re- suits. Significant decreases were detected in plasma levels of miR-143 and miR-145 in patients with CAD compared with non-significant CAD or healthy subiects. In addition, miR-143 and miR-145 were identified as independent factors associated with the severity of atherosclerosis (miR-143, r=- 0. 440, P = 0. 001; miR-145,r= --0. 459, P = 0. 015). Furthermore, receiver operating characteristic curves analysis showed miR-143 and miR-145 were diagnostic predictors in CAD patients, with an area under curve of 0. 884 and 0. 909, respectively. Conclusions: miR143 and miR145 may function as useful biomarkers with high sensitivity and specificity in the diagnosis of initiation and development of coronary atherosclerosis.
关 键 词:冠心病 微小RNA MIR-143 MIR-145 生物标志物
分 类 号:R541.4[医药卫生—心血管疾病]
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.147